Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment

Toxicologic Pathology

Volumn 38, Issue 5, 2010, Pages 799-809

  Mohutsky, Michael A ^a   Romeike, Annette ^b   Meador, Vince ^c   Lee, William M ^d   Fowler, John ^e   Francke Carroll, Sabine ^f  

^a ELI LILLY AND COMPANY   (United States)

^b IPSAR Consultancy ^*  (France)

^c 206 Carnegie Center   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Independent Consultant   (United Kingdom)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

drug metabolizing enzymes; enzyme induction; hepatic; induction; metabolism; risk assessment

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 1A; CYTOCHROME P450 2C19; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; PARACETAMOL; PREGNANE X RECEPTOR; ROSIGLITAZONE; TROGLITAZONE;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; HAZARD ASSESSMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; TOXICITY;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENZYME INDUCTION; HUMANS; LIVER; RISK ASSESSMENT; TOXICITY TESTS; XENOBIOTICS;

EID: 77958524342     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310375099     Document Type: Review

References (105)

1. Albano, E. (2006). Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 65, 278-290.
2. Albano, E., Tomasi, A., Persson, J.O., Terelius, Y., Goria-Gatti, L., Ingelman-Sundberg, M., and Dianzani, M.U. (1991). Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols. Biochem Pharmacol 41, 1895-1902.
3. Andersson, T., Bergstrand, R., Cederberg, C., Eriksson, S., Lagerstrom, P.O., and Skanberg, I. (1991). Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 101, 943-947.
4. Ayrton, A.D., Ioannides, C., and Parke, D.V. (1991). Induction of the cytochrome P450 I and IV families and peroxisomal proliferation in the liver of rats treated with benoxaprofen. Possible implications in its hepatotoxicity. Biochem Pharmacol 42, 109-115.
5. Back, D.J., Grimmer, S.F., Orme, M.L., Proudlove, C., Mann, R.D., and Breckenridge, A.M. (1988). Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 25, 527-532.
6. Botts, S., Ennulat, D., Francke-Carroll, S., Graham, M., Maronpot, R., and Mohutsky, M. (2010). Introduction to hepatic drug metabolizing enzyme induction studies in drug safety evaluation studies. Toxicol Pathol 38, 794-796.
7. Breckenridge, A. (1987). Enzyme induction in humans. Clinical aspects-an overview. Pharmacol Ther 33, 95-99.
8. Bu, H.Z., Kang, P., Deese, A.J., Zhao, P., and Pool, W.F. (2005). Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos 33, 1920-1924.
9. Burk, O., Arnold, K.A., Nussler, A.K., Schaeffeler, E., Efimova, E., Avery, B.A., Avery, M.A., Fromm, M.F., and Eichelbaum, M. (2005). Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67, 1954-1965.
10. Chien, J.Y., Thummel, K.E., and Slattery, J.T. (1997). Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 25, 1165-1175.
11. Chu, V., Einolf, H.J., Evers, R., Kumar, G., Moore, D., Ripp, S., Silva, J., Sinha, V., Sinz, M., and Skerjanec, A. (2009). In vitro and in vivo induction of cytochrome p450: A survey of the current practices and recommendations: A Pharmaceutical Research and Manufacturers of America perspective. Drug Metab Dispos 37, 1339-1354.
12. Conney, A.H. (1967). Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19, 317-366.
13. Dickerson, J.W., Basu, T.K., and Parke, D.V. (1976). Effect of protein-energy nutrition on the activity of hepatic microsomal drug-metabolizing enzymes in growing rats. J Nutr 106, 258-264.
14. Ennulat, D., Boone, L., Clemo, F., Graham, M., Ledieu, D., Magid-Slav, M., Walker, D., and Botts, S. (2010). Effects of hepatic drug metabolizing enzyme induction on clinical pathology parameters in animals and man. Toxicol Pathol 38, 808-826.
15. Fichtenbaum, C.J., and Gerber, J.G. (2002). Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41, 1195-1211.
16. Frantz, R.P., and Nguyen, T.T. (1998). Rezulin (troglitazone) greatly increases cyclosporine metabolism. J Heart Lung Transplant 17, 1037-38.
17. Friedmann, P.S., Strickland, I., Pirmohamed, M., and Park, B.K. (1994). Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 130, 598-604.
18. Goodwin, B., Hodgson, E., D'sCosta, D.J., Robertson, G.R., and Liddle, C. (2002). Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 62, 359-365.
19. Gracon, S.I., Knapp, M.J., Berghoff, W.G., Pierce, M., DeJong, R., Lobbestael, S.J., Symons, J., Dombey, S.L., Luscombe, F.A., and Kraemer, D. (1998). Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 12, 93-101.
20. Graham M.J., and Lake B.G. (2008). Induction of drug metabolism: Species differences and toxicological relevance. Toxicology. 254 (3). 184-191.
21. Gupta, A., Mugundu, G.M., Desai, P.B., Thummel, K.E., and Unadkat, J.D. (2008). Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: Studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36, 1172-1180.
22. Gut, J., Christen, U., and Huwyler, J. (1993). Mechanisms of halothane toxicity: Novel insights. Pharmacol Ther 58, 133-155.
23. Hariparsad, N., Carr, B.A., Evers, R., and Chu, X. (2008). Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36, 1046-1055.
24. Harris, R.Z., Inglis, A.M., Miller, A.K., Thompson, K.A., Finnerty, D., Patterson, S., Jorkasky, D.K., and Freed, M.I. (1999). Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol 39, 1189-1194.
25. Hersh, E.V., Pinto, A., and Moore, P.A. (2007). Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 29 Suppl, 2477-2497.
26. Hewitt, N.J., Lecluyse, E.L., and Ferguson, S.S. (2007). Induction of hepatic cytochrome P450 enzymes: Methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37, 1196-1224.
27. Jyrkkarinne, J., Windshugel, B., Makinen, J., Ylisirnio, M., Perakyla, M., Poso, A., Sippl, W., and Honkakoski, P. (2005). Amino acids important for ligand specificity of the human constitutive androstane receptor. J Biol Chem 280, 5960-5971.
28. Kerr, B.M., Thummel, K.E., Wurden, C.J., Klein, S.M., Kroetz, D.L., Gonzalez, F.J., and Levy, R.H. (1994). Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47, 1969-1979.
29. Khetani, S.R., and Bhatia, S.N. (2008). Microscale culture of human liver cells for drug development. Nat Biotechnol 26, 120-126.
30. Kitamura, R., Asanoma, H., Nagayama, S., and Otagiri, M. (2008). Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3Hindol-3- ylidene)methyl]-2,4-dimethyl-1H-pyrro le-3-propanoic acid (TSU-68). Drug Metab Dispos 36, 1003-1009.
31. Kitamura, R., Matsuoka, K., Nagayama, S., and Otagiri, M. (2008). Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68. Drug Metab Pharmacokinet 23, 421-427.
32. Kitamura, R., Yamamoto, Y., Nagayama, S., and Otagiri, M. (2007). Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrr ole-3-propanoic acid) during oral administration twice a day to rats. Drug Metab Dispos 35, 1611-1616.
33. Kluwe, W.M., and Hook, J.B. (1981). Comparative induction of xenobiotic metabolism in rodent kidney, testis and liver by commercial mixtures of polybrominated biphenyls and polychlorinated biphenyls, phenobarbital and 3-methylcholanthrene: Absolute and temporal effects. Toxicology 20, 259-273.
34. Kluwe, W.M., Hook, J.B., and Bernstein, J. (1982). Synergistic toxicity of carbon tetrachloride and several aromatic organohalide compounds. Toxicology 23, 321-336.
35. Kocarek, T.A., Schuetz, E.G., Strom, S.C., Fisher, R.A., and Guzelian, P.S. (1995). Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 23, 415-421.
36. Koup, J.R., Anderson, G.D., and Loi, C.M. (1998). Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol. J Clin Pharmacol 38, 815-18.
37. Kuffner, E.K., Green, J.L., Bogdan, G.M., Knox, P.C., Palmer, R.B., Heard, K., Slattery, J.T., and Dart, R.C. (2007). The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients-a multicenter randomized study. BMC Med 5, 13.
38. Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., and Chalasani, N. (2008). Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals. Hepatology 47, 2003-2009.
39. Lau, W.C., Gurbel, P.A., Watkins, P.B., Neer, C.J., Hopp, A.S., Carville, D.G., Guyer, K.E., Tait, A.R., and Bates, E.R. (2004). Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109, 166-171.
40. Le, N.B., Pham, T.Y., Nguyen, B.N., Dang, C.T., Pham, T.L., and Le, D.C. (1999). Efficacy and effectiveness of five day treatment of uncomplicated falciparum with artemisinin or artesunate in Vietnam. Southeast Asian J Trop Med Public Health 30, 3-6.
41. Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., Moore, J.T., and Kliewer, S.A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102, 1016-1023.
42. Lin, J.H. (2006). CYP induction-mediated drug interactions: In vitro assessment and clinical implications. Pharm Res 23, 1089-1116.
43. Loi, C.M., Stern, R., Koup, J.R., Vassos, A.B., Knowlton, P., and Sedman, A.J. (1999). Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. J Clin Pharmacol 39, 410-417.
44. Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., Rizzo, C., Jolley, S., Gilbert, D., Downey, A., Mudra, D., Graham, R., Carroll, K., Xie, J., Madan, A., Parkinson, A., Christ, D., Selling, B., LeCluyse, E., and Gan, L.S. (2002). CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30, 795-804.
45. Ma, X., Shah, Y., Cheung, C., Guo, G.L., Feigenbaum, L., Krausz, K.W., Idle, J.R., and Gonzalez, F.J. (2007). The PREgnane X receptor gene-humanized mouse: A model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35, 194-200.
46. Madden, S., Spaldin, V., Hayes, R.N., Woolf, T.F., Pool, W.F., and Park, B.K. (1995). Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 25, 103-116.
47. Maling, H.M., Stripp, B., Sipes, I.G., Highman, B., Saul, W., and Williams, M.A. (1975). Enhanced hepatotoxicity of carbon tetrachloride, thioacetamide, and dimethylnitrosamine by pretreatment of rats with ethanol and some comparisons with potentiation by isopropanol. Toxicol Appl Pharmacol 33, 291-308.
48. Maronpot, R., Dambach, D., Flake, G., Takanori, H., Mueller, G., Mueller, R., Nyska, A., Singh, B., Ward, J., and Yoshizawa, K. (2010). Hepatic enzyme induction-Microscopic and ultrastructural appearance. Toxicol Pathol.
49. Martignoni, M., Groothuis, G.M., and de Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2, 875-894.
50. McGinnity, D.F., Zhang, G., Kenny, J.R., Hamilton, G.A., Otmani, S., Stams, K.R., Haney, S., Brassil, P., Stresser, D.M., and Riley, R.J. (2009). Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: Human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37, 1259-1268.
51. McLean, A.E., and McLean, E.K. (1966). The effect of diet and 1,1,1-tri-chloro-2,2-bis-(p-chlorophenyl)ethane (DDT) on microsomal hydroxylating enzymes and on sensitivity of rats to carbon tetrachloride poisoning. Biochem J 100, 564-571.
52. Mills, J.B., Rose, K.A., Sadagopan, N., Sahi, J., and de Morais, S.M. (2004). Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 309, 303-309.
53. Moore, J.T., and Kliewer, S.A. (2000). Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153, 1-10.
54. Nelson, S.D. (1990). Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 10, 267-278.
55. Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J., and Kivisto, K.T. (2003). Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 42, 819-850.
56. Novartis (2009). Tegretol-Prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf. Accessed November 2009.
57. Nowak, S.N., Edwards, D.J., Clarke, A., Anderson, G.D., and Jaber, L.A. (2002). Pioglitazone: Effect on CYP3A4 activity. J Clin Pharmacol 42, 1299-1302.
58. Oscarson, M., Zanger, U.M., Rifki, O.F., Klein, K., Eichelbaum, M., and Meyer, U.A. (2006). Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 80, 440-456.
59. Pal, D., and Mitra, A.K. (2006). MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78, 2131-2145.
60. Park, B.K., Kitteringham, N.R., Pirmohamed, M., and Tucker, G.T. (1996). Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications. Br J Clin Pharmacol 41, 477-91.
61. Park, M.H., Pelegrin, D., Haug, M.T., 3rd, and Young, J.B. (1998). Troglitazone, a new antidiabetic agent, decreases cyclosporine level. J Heart Lung Transplant 17, 1139-1140.
62. Pearce, R.E., Lu, W., Wang, Y., Uetrecht, J.P., Correia, M.A., and Leeder, J.S. (2008). Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3- dihydroxycarbamazepine. Drug Metab Dispos 36, 1637-1649.
63. Pearce, R.E., Uetrecht, J.P., and Leeder, J.S. (2005). Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 33, 1819-1826.
64. Perrot, N., Nalpas, B., Yang, C.S., and Beaune, P.H. (1989). Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest 19, 549-555.
65. Quattrochi, L.C., and Tukey, R.H. (1993). Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: Transcriptional activation of the human CYP1A1 gene. Mol Pharmacol 43, 504-508.
66. Ramadoss, P., and Perdew, G.H. (2004). Use of 2-azido-3-[125I]iodo-7,8- dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. Mol Pharmacol 66, 129-136.
67. Raucy, J., Warfe, L., Yueh, M.F., and Allen, S.W. (2002). A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther 303, 412-423.
68. Ripp, S.L., Mills, J.B., Fahmi, O.A., Trevena, K.A., Liras, J.L., Maurer, T.S., and de Morais, S.M. (2006). Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34, 1742-1748.
69. Rizzo, N., Padoin, C., Palombo, S., Scherrmann, J.M., and Girre, C. (1996). Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol 49, 491-495.
70. Roffey, S.J., Cole, S., Comby, P., Gibson, D., Jezequel, S.G., Nedderman, A.N., Smith, D.A., Walker, D.K., and Wood, N. (2003). The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31, 731-741.
71. Ronis, M.J.J., and Ingelman-Sundberg, M. (1999). Induction of human drug-metabolizing enzymes: Mechanisms and implications. In Handbook of Drug Metabolism. (T. F. Woolf, ed.). pp. 239-262, Marcel Dekker, Inc., New York, NY.
72. Ronis, M.J.J., Lindros, K.O., and Ingelman-Sundberg, M. (1996). The CYP2E family.76. Cytochrome P450: Metabolic and Toxicological Aspects (C. Ioannides, ed.). pp. 211-239, CRC Press, Boca Raton, FL.
73. Rost, K.L., Brosicke, H., Brockmoller, J., Scheffler, M., Helge, H., and Roots, I. (1992). Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52, 170-180.
74. Rost, K.L., Brosicke, H., Heinemeyer, G., and Roots, I. (1994). Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 20, 1204-1212.
75. Roth R.A., and Ganey P.E. (2010). Intrinsic versus idiosyncratic drug-induced hepatotoxicity-two villains or one? J Pharmacol Exp Ther 332 (3). 692-97.
76. Ruschitzka, F., Meier, P.J., Turina, M., Luscher, T.F., and Noll, G. (2000). Acute heart transplant rejection due to Saint John's wort. Lancet 355, 548-549.
77. Sahi, J., Black, C.B., Hamilton, G.A., Zheng, X., Jolley, S., Rose, K.A., Gilbert, D., LeCluyse, E.L., and Sinz, M.W. (2003). Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31, 439-446.
78. Scheer, N., Ross, J., Rode, A., Zevnik, B., Niehaves, S., Faust, N., and Wolf, C.R. (2008). A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118, 3228-3239.
79. Schoedel, K.A., and Tyndale, R.F. (2003). Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: Summary and implications. Biochim Biophys Acta 1619, 283-290.
80. Sciele Pharma. Cognex - Prescribing Information. Available at: http://www.sciele.com/PI/Cognex%20PI.pdf. Accessed November 2009.
81. Seawright, A.A., and McLean, A.E. (1967). The effect of diet on carbon tetrachloride metabolism. Biochem J 105, 1055-1060.
82. Seeff, L.B., Cuccherini, B.A., Zimmerman, H.J., Adler, E., and Benjamin, S.B. (1986). Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 104, 399-404.
83. Senior, J.R. (2007). Regulatory perspectives. In Drug-Induced Liver Disease, 2 nd edition (N. Kaplowitz and L. D. DeLeve, eds.). pp. 771-789, Informa Healthcare, New York, NY.
84. Sessa, C., Vigano, L., Grasselli, G., Trigo, J., Marimon, I., Llado, A., Locatelli, A., Ielmini, N., Marsoni, S., and Gianni, L. (2006). Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 42, 171-178.
85. Shou, M., Hayashi, M., Pan, Y., Xu, Y., Morrissey, K., Xu, L., and Skiles, G.L. (2008). Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36, 2355-2370.
86. Shuldiner, A.R., O'sConnell, J.R., Bliden, K.P., Gandhi, A., Ryan, K., Horenstein, R.B., Damcott, C.M., Pakyz, R., Tantry, U.S., Gibson, Q., Pollin, T.I., Post, W., Parsa, A., Mitchell, B.D., Faraday, N., Herzog, W., and Gurbel, P.A. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857.
87. Simonsson, U.S., Jansson, B., Hai, T.N., Huong, D.X., Tybring, G., and Ash-ton, M. (2003). Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74, 32-43.
88. Smith, D.A. (2000). Induction and drug development. Eur J Pharm Sci 11, 185-189.
89. Smith, D.A., and Obach, R.S. (2005). Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 33, 1409-1417.
90. Smith, D.A., and Obach, R.S. (2009). Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22, 267-279.
91. Soars, M.G., Petullo, D.M., Eckstein, J.A., Kasper, S.C., and Wrighton, S.A. (2004). An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32, 140-148.
92. Spaldin, V., Madden, S., Adams, D.A., Edwards, R.J., Davies, D.S., and Park, B.K. (1995). Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 23, 929-934.
93. Takahashi, T., Lasker, J.M., Rosman, A.S., and Lieber, C.S. (1993). Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology 17, 236-45.
94. Thummel, K.E., Slattery, J.T., Ro, H., Chien, J.Y., Nelson, S.D., Lown, K.E., and Watkins, P.B. (2000). Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 67, 591-599.
95. Tucker, G.T., Houston, J.B., and Huang, S.M. (2001). Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18, 1071-1080.
96. U.S. Department of Health and Human Services, F. D. A., Center for Drug Evaluation and Research (CDER) (2006). Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, Draft Guidance. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM072101.pdf. Accessed November 2009.
97. U.S. Department of Health and Human Services, F. D. A., Center for Drug Evaluation and Research (CDER) (2008). Safety Testing of Drug Metabolites. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm079266.pdf.AccessedNovember2009.
98. Uetrecht, J. (2007). Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47, 513-539.
99. Venkatesan, K. (1992). Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 22, 47-65.
100. Waterman, C.L., Currie, R.A., Cottrell, L.A., Dow, J., Wright, J., Waterfield, C.J., and Griffin, J.L. (2010) An integrated functional genomic study of acute phenobarbital exposure in the rat. BMC Genomics 11, 9.
101. Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I., and Lewis, K.W. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271, 992-998.
102. Williams, J.A., Hyland, R., Jones, B.C., Smith, D.A., Hurst, S., Goosen, T.C., Peterkin, V., Koup, J.R., and Ball, S.E. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32, 1201-1208.
103. Wolkenstein, P., Tan, C., Lecoeur, S., Wechsler, J., Garcia-Martin, N., Charue, D., Bagot, M., and Beaune, P. (1998). Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Interact 113, 39-50.
104. Wrighton, S.A., Schuetz, E.G., Watkins, P.B., Maurel, P., Barwick, J., Bailey, B.S., Hartle, H.T., Young, B., and Guzelian, P. (1985). Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. Mol Pharmacol 28, 312-321.
105. Xiaodong, S., Gatti, G., Bartoli, A., Cipolla, G., Crema, F., and Perucca, E. (1994). Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. Ther Drug Monit 16, 248-250.